
    
      After exiting VGFT-OD 0910, patients will be enrolled into RANGE, a longterm extension trial
      evaluating the safety and efficacy of aflibercept IAI utilizing a "treat and extend" regimen.
      Using pre-specified re-treatment criteria, treatment intervals will be variable with dosing
      of the active treatment at least every 12 weeks.
    
  